Tm Bioscience to supply Oklahoma State's newborn screening program
TM Bioscience Corporation announced it has signed an agreement with the Oklahoma State Department of Health to supply its Newborn Screening Program (NSP) with Tag-It(TM) Analyte Specific reagents for the CFTR gene.
"Oklahoma is one of a growing number of U.S. States incorporating genetic testing into their newborn screening programs. This trend creates a significant market opportunity for our CFTR ASR*, which competitively address the needs of this market," said Greg Hines, President and CEO of Tm Bioscience. The NSP is a collaborative program between Family Health Services and the Public Health Laboratory at the Oklahoma State Department of Health. All babies born in Oklahoma are screened for congenital hypothyroidism, galactosemia, phenylketonuria (PKU), sickle cell disease, and since Feb.14, 2005, cystic fibrosis and congenital adrenal hyperplasia. Each year the NSP laboratory screens approximately 50,000 infants and provides comprehensive follow-up services to ensure repeat testing is achieved for 1,300 newborns identified at risk for a disorder or genetic trait condition. Approximately 40 newborns are identified with a disorder annually and receive comprehensive follow services to ensure treatment and referral to pediatric subspecialty is achieved promptly. To promote the health of Oklahoma infants, the NSP is continuing to expand the screening test panel for the genetic disorder medium chain acyl-CoA dehydrogenase deficiency (MCAD).
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
